参考文献/References:
[1] 张 辉,张庆桥,袁 磊,等.CalliSpheres D-TACE与c-TACE治疗原发性肝癌对肝纤维化和肝功能的影响[J].介入放射学杂志,2024,33:259-263.
Zhang H,Zhang Q Q,Yuan L,et al.The effect of CalliSpheres DEB-TACE and c-TACE on liver fibrosis and liver function in treating primary hepatocellular carcinoma[J],J Intervent Radiol,2024,33:259-263.
[2]Yuan Y,He W,Yang Z,et al.TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus:a propensity score matching study[J].Int J Surg,2023,109:1222-1230.
[3]Fan W,Zhu B,Chen S,et al.Survival in patients with recurrent intermediate-stage hepatocellular carcinoma:sorafenib plus TACE vs TACE Alone Randomized Clinical Trial[J].JAMA Oncol,2024,10:1047-1054.
[4]Ai X,Wang H,Yang Y,et al.Four indices on Gd-EOB-DTPA-enhanced MRI can estimate liver functional reserve compared to ICG-R15:a systematic review and meta-analysis[J].Clin Imaging,2023,102:1-8.
[5]Yan M,Zhang X,Zhang B,et al.Deep learning nomogram based on Gd-EOB-DTPA MRI for predicting early recurrence in hepatocellular carcinoma after hepatectomy[J].Eur Radiol,2023,33:4949-4961.
[6]Wang D,Zhang Y,Lyu R,et al.LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma:diagnostic performance and the added value of ancillary features[J].Abdom Radiol(NY),2024,49:3045-3055.
[7]中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中华消化外科杂志,2020,19:1-20.
Medical Administration Bureau of the National Health Commission of the People's Republic of China.Standardization for diagnosis and treatment of hepatocellular carcinoma(2019 edition)[J].Chin J Digest Surg,2020,19:1-20.
[8]Kanmaniraja D,Dellacerra G,Holder J,et al.Liver Imaging Reporting and Data System(LI-RADS)v2018:Review of the CT/MRI diagnostic categories[J].Can Assoc Radiol J,2021,72:142-149.
[9]Kim SW,Joo I,Kim HC,et al.LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI:diagnostic performance compared to mRECIST and added value of ancillary features[J].Eur Radiol,2020,30:2861-2870.
[10]Liu B,Zhang Y,Chen H,et al.The combination of transcatheter arterial chemoembolisation(TACE)and thermal ablation versus TACE alone for hepatocellular carcinoma[J].Cochrane Database Syst Rev,2022,1:CD013345.
[11]Mo A,Lin B,Chen D.Efficacy of sequential TACE on primary hepatocellular carcinoma with microvascular invasion after radical resection:a systematic review and meta-analysis[J].World J Surg Oncol,2023,21:277-287.
[12]Liu D,Qiao Z,Xu L,et al.Gd-EOB-DTPA enhanced MRI features of liver hemangiomatosis coexistent with GCH[J].Curr Med Imaging,2022,18:1390-1395.
[13]Bhattacharyya T,Mallett CL,Shapiro EM.MRI-based cell tracking of OATP-expressing cell transplants by pre-labeling with Gd-EOB-DTPA[J].Mol Imaging Biol,2024,26:233-239.
[14]Mao Y,Wang J,Zhu Y,et al.Gd-EOB-DTPA-enhanced MRI radiomic features for predicting histological grade of hepatocellular carcinoma[J].Hepatobiliary Surg Nutr,2022,11:13-24.
[15]悦笑斐,杨红丽,吴林霞,等.基于MRI的LI-RADS 2018版评价肝癌介入术后肿瘤活性的研究[J].临床放射学杂志,2022,41:2236-2240.
Yue X F,Yang H L,Wu L X,et al.LI-RADS Version 2018 for evaluating tumor viability of hepatocellular carcinoma after interventional procedures on MRI[J].J Clin Radiol,2022,41:2236-2240.
[16]Yu Y,Fan Y,Wang X,et al.Gd-EOB-DTPA-enhanced MRI radiomics to predict vessels encapsulating tumor clusters(VETC)and patient prognosis in hepatocellular carcinoma[J].Eur Radiol,2022,32:959-970.
[17]Zheng R,Zhang X,Liu B,et al.Comparison of non-radiomics imaging features and radiomics models based on contrast-enhanced ultrasound and Gd-EOB-DTPA-enhanced MRI for predicting microvascular invasion in hepatocellular carcinoma within 5 cm[J].Eur Radiol,2023,33:6462-6472.
[18]Shi Z,Cai W,Feng X,et al.Radiomics analysis of Gd-EOB-DTPA enhanced hepatic MRI for assessment of functional liver reserve[J].Acad Radiol,2022,29:213-218.
[19]Marth AA,Auer TA,Walter-Rittel TC,et al.Gd-EOB-DTPA-MRCP to localize bile leakage after liver trauma and surgery:impact on treatment and outcome[J].Eur Radiol,2023,33:5933-5942.
[20]Kuwano A,Tanaka K,Yada M,et al.Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRI[J].Mol Clin Oncol,2022,16:53-62.
[21]Inokuchi Y,Fujikawa H,Uematsu M,et al.Transitional phase Gd-EOB-DTPA-enhanced MRI:Visual assessment of hepatic function and fibrosis based on uptake rate of Gd-EOB-DTPA[J].Eur J Radiol,2022,156:e110550.
(收稿日期:2025-09-24)
(本文编辑:新 宇)
相似文献/References:
[1]郭丽萍,张晓玲,王莉娜.经导管肝动脉化疗栓塞联合高强度聚焦超声治疗原发性肝癌的护理[J].介入放射学杂志,2010,(04):328.
GUO Liping,ZHANG Xiaoling,WANG Lina.The nursing care for patients of hepatocellular carcinoma treated with transcatheter hepatic arterial chemoembolization and high intensive focus ultrasound[J].J Intervent Med,2010,(09):328.
[2]沈海洋,杨光,刘瑞宝,等.肝右叶前、后段原发性肝癌动脉化疗栓塞术后近期疗效比较[J].介入放射学杂志,2010,(05):382.
SHEN Haiyang,YANG Guang,LIU Ruibao,et al.Short－term effects of TACE for primary hepatocellular carcinoma of the right hepatic lobe：a comparison between the lesions in anterior segments and the lesions in posterior segments[J].J Intervent Med,2010,(09):382.
[3]池嘉昌,沈加林,许建荣,等.全肝CT灌注成像在原发性肝癌TACE术后局部病灶活性评估中的临床应用[J].介入放射学杂志,2010,(07):540.
CHI Jiachang,SHEN Jialin,XU Jianrong,et al.Clinical application of whole－liver perfusion－enhanced CT imaging in evaluating the activity of residual hepatocellular carcinoma after TACE[J].J Intervent Med,2010,(09):540.
[4]翁志成,杨维竹,江娜,等.CT引导下１２５I放射性粒子植入治疗肝癌门静脉癌栓的疗效评价[J].介入放射学杂志,2010,(07):535.
WENG Zhicheng,YANG Weizhu,JIANG Na,et al.Evaluation of CT－guided１２５I seed implantation combined with transcatheter arterial chemoem－bolization in treating portal vein tumor thrombus associated with hepatocellular carcinoma[J].J Intervent Med,2010,(09):535.
[5]王悍 王精兵 张贵祥 王麟川.肝细胞癌动脉化疗栓塞术后并发脑梗死一例[J].介入放射学杂志,2005,(04):442.
WANG Han WANG Jing-bing ZHANG Gui-xiang WANG Lin-chuan.Cerebral infarction aften transaterial shemoembolization for hepatocellular carcinoma a cage report[J].J Intervent Med,2005,(09):442.
[6]张绪敬,程佩芳,董光,等.原发性肝癌经导管化疗、栓塞前后血中凝血酶原变化的研究[J].介入放射学杂志,1992,(01):33.
[7]欧阳墉,马和平,张学军,等.肝细胞癌的鉴别诊断——附10例分析[J].介入放射学杂志,1996,(01):40.
[8]周斌,李征然,钱结胜,等.原发性肝癌肝移植后肿瘤复发的化疗栓塞治疗[J].介入放射学杂志,2009,(03):185.
ZHOU Bin,LI Zhengran,QIAN Jiesheng,et al.Chemoembolization for recurrent hepatocellular carcinoma after liver transplantation[J].J Intervent Med,2009,(09):185.
[9]黄渊全,贾中芝,冯耀良,等.CT灌注成像在肝癌TACE术后疗效评价中的应用价值[J].介入放射学杂志,2009,(06):437.
HUANG Yuan-quan,JIA Zhong-zhi,FENG Yao-liang,et al.Clinical application of CT perfusion imaging in estimating the efficacy of transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma[J].J Intervent Med,2009,(09):437.
[10]王惠文,刘瑞宝,刘 岩,等.原发性肝癌ＴＡＣＥ后ＦＡＫ、ＮＦκＢｐ６５表达及意义[J].介入放射学杂志,2011,(08):621.
WANG Hui-wen,LIU Rui-bao,LIU Yan,et al.The expression and significance of FAK and NF-κBp65 in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].J Intervent Med,2011,(09):621.